{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:18:53Z","timestamp":1787750333010,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Monoclonal antibodies (mAbs) are frequently used in the treatment of various types of cancer and autoimmune diseases, but their causal association with Gastrointestinal (GI) disorders is still unclear. The purpose of this study is to evaluate the frequency and nature of GI adverse events (AEs) associated with mAbs reported in the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>The study\u2019s primary objective was to investigate the GI-AEs linked with mAbs, determine the demographic trends, and evaluate the clinical characteristics (age groups, seriousness, fatality, etc.) from the reported cases. Secondary objectives included using disproportionality signal analysis to find mAb-AEs combinations with significant associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>\n                      Cases involving mAbs from the FAERS database were examined for the period from first authorization until June 30, 2023. The AEs were taken from the \u201cGI Disorders\u201d System Organ Class as standardized Preferred Terms. The characteristics of the cases, such as gender, age, seriousness, and co-suspect drug usage, were examined in detail. Proportional relative risk, IC025,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      , and Ncomb metrics were used in disproportionality analysis to find the meaningful associations between a particular mAb and GI-AE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>A total of 115,346 cases were evaluated, and the most common GI-AEs were caused by rituximab, bevacizumab, and denosumab. Constipation, vomiting, nausea, abdominal pain, and diarrhea were the most commonly reported AEs. 89.17% of cases had serious AEs, and 14.33% had fatal outcomes. Bevacizumab, atezolizumab, and rituximab had the highest death rates. 29 signals were detected by performing the disproportionality analysis for mAbs-GI-AEs combinations having significant values, especially for enterocolitis, ascites, GI perforation, and some other AEs as well, from GI disorders. The highest number of signals was identified by bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>This study highlights the strong correlation between mAbs and GI disorders, especially for mAbs such as atezolizumab, rituximab, and bevacizumab. The results emphasise the necessity of increased pharmacovigilance to keep an eye on these AEs and enhance patient safety. Improving patient safety during mAb therapy requires constant safety surveillance and additional research. Further investigation into the mechanisms underlying these relationships could lead to more effective management options for patients undergoing mAb therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_416_25","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:00:30Z","timestamp":1782410430000},"page":"375-386","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal adverse events related to monoclonal antibodies: A comprehensive evaluation of data from the FDA Adverse Event Reporting System database"],"prefix":"10.4103","volume":"58","author":[{"given":"Nitin","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanandan","family":"Kalaiselvan","sequence":"additional","affiliation":[{"name":"Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India, Ghaziabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Kumar","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R1-20260626","first-page":"2183","article-title":"On the development of immunity to diphtheria and tetanus in animals","volume":"90","author":"Behring","year":"1965","journal-title":"Dtsch Med Wochenschr"},{"key":"R2-20260626","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"R3-20260626","first-page":"807","article-title":"Therapeutic use of monoclonal antibodies: General aspects and challenges for drug delivery","author":"Quinteros","year":"2017","journal-title":"Nanostructures for Drug Delivery, In Micro and Nano Technologies, Elsevier eBooks"},{"key":"R4-20260626","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-014-1687-9","article-title":"Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: A meta-analysis with a focus on different subgroups","volume":"70","author":"Qi","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-20260626","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R6-20260626","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R8-20260626","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R9-20260626","doi-asserted-by":"crossref","first-page":"e30280","DOI":"10.7554\/eLife.30280","article-title":"The benefits of data mining","volume":"6","author":"Bone","year":"2017","journal-title":"Elife"},{"key":"R10-20260626","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The newly available FAERS public dashboard: Implications for health care professionals","volume":"54","author":"Kumar","year":"2019","journal-title":"Hosp Pharm"},{"key":"R13-20260626","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00228-024-03727-0","article-title":"Neuronal toxicity of monoclonal antibodies (mAbs): An analysis of post-marketing reports from FDA adverse event reporting system (FAERS) safety database","volume":"80","author":"Kumar","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20260626","doi-asserted-by":"crossref","first-page":"610806","DOI":"10.3389\/fphar.2020.610806","article-title":"Personalized medicine of monoclonal antibodies in inflammatory bowel disease: Pharmacogenetics, therapeutic drug monitoring, and beyond","volume":"11","author":"Di Paolo","year":"2020","journal-title":"Front Pharmacol"},{"key":"R15-20260626","doi-asserted-by":"crossref","first-page":"760013","DOI":"10.3389\/fphar.2021.760013","article-title":"Safety profile of monoclonal antibody compared with traditional anticancer drugs: An analysis of Henan province spontaneous reporting system database","volume":"12","author":"Jiao","year":"2021","journal-title":"Front Pharmacol"},{"key":"R16-20260626","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjc.6606074","article-title":"Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study","volume":"104","author":"Leighl","year":"2011","journal-title":"Br J Cancer"},{"key":"R17-20260626","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ags3.12312","article-title":"Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab","volume":"4","author":"Yoshimoto","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"R18-20260626","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00280-009-1062-1","article-title":"Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation","volume":"64","author":"Cornejo","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R19-20260626","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1200\/JCO.2010.31.8899","article-title":"Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma","volume":"29","author":"Blombery","year":"2011","journal-title":"J Clin Oncol"},{"key":"R20-20260626","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1634\/theoncologist.2014-0169","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Kuten-Shorrer","year":"2014","journal-title":"Oncologist"},{"key":"R21-20260626","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"R22-20260626","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3748\/wjg.v18.i16.1871","article-title":"Colitis associated with biological agents","volume":"18","author":"Freeman","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R23-20260626","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8507-21","article-title":"Pembrolizumab-induced focal pancreatitis diagnosed by endoscopic ultrasound-guided fine-needle aspiration","volume":"61","author":"Ikemoto","year":"2022","journal-title":"Intern Med"},{"key":"R24-20260626","doi-asserted-by":"crossref","first-page":"1225919","DOI":"10.3389\/fphar.2023.1225919","article-title":"Indication and adverse event profiles of denosumab and zoledronic acid: Based on U. S. FDA adverse event reporting system (FAERS)","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"R26-20260626","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-020-01715-7","article-title":"Oral mucositis: The hidden side of cancer therapy","volume":"39","author":"Pulito","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"R27-20260626","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848231158549","article-title":"Gastrointestinal injury induced by immunomodulators: A review article","volume":"16","author":"Zhang","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"R28-20260626","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clbc.2019.06.016","article-title":"Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"20","author":"Bines","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"R29-20260626","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1158\/1535-7163.MCT-17-1268","article-title":"Mechanistic investigations of diarrhea toxicity induced by anti-HER2\/3 combination therapy","volume":"17","author":"Moisan","year":"2018","journal-title":"Mol Cancer Ther"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_416_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:25:31Z","timestamp":1787747131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_416_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_416_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}